Lei et al. — Berberine and adiposity in adults with obesity and MASLD
No significant reduction in visceral or liver fat versus placebo.
The record
- Year
- 2026
- Design
- Six-month randomized, double-blind, placebo-controlled trial
- Population
- 337 adults with obesity and metabolic liver disease, without diabetes
One clinical population; secondary biomarker findings were exploratory.